Julian’s Law as Affirmative Defense — What It Does Not Do

Last verified: May 2026

Authorization vs. Affirmative Defense

The distinction matters. A "fully legal authorization" — the model used in operational state medical-cannabis programs in Florida, Alabama, Mississippi, Louisiana, and Utah — gives a registered patient a state-issued credential that, when presented, prevents an arrest in the first place. The patient walks into a regulated in-state dispensary, presents a card, purchases product whose chain of custody is tracked by the state, and is statutorily protected from prosecution and (in most operational states) from at least some employment and housing discrimination.

Julian’s Law operates differently. It does not create a card, does not create a registry, and does not create a regulated supply. What it does do is provide a defense at trial: if a patient with Lennox-Gastaut Syndrome, Dravet Syndrome, or another "severe form of epilepsy that is not adequately treated by traditional medical therapies" is charged with possession of low-THC, high-CBD oil that meets the statutory specifications (≥15% CBD, ≤0.9% THC), and the patient has a neurologist’s recommendation through an approved teaching hospital, the patient may raise Julian’s Law as an affirmative defense to prosecution under § 44-53-370. The patient bears the burden of proving the defense’s elements; the law does not prevent the arrest, the booking, the seizure of the product, or the collateral consequences (including the § 56-1-286 mandatory six-month driver’s license suspension on any conviction). See possession penalties.

What Julian’s Law Lacks

Compared to operational medical-cannabis frameworks, Julian’s Law lacks every infrastructure element a working program requires:

• No in-state cultivation, processing, or dispensing. The 2014 statute did not authorize any South Carolina facility to grow, manufacture, or sell qualifying CBD oil. There is no state-issued cultivation license, no processor license, no dispensary license, and no state-administered seed-to-sale tracking. Twelve years after enactment, the supply infrastructure that the law contemplated has never come into existence in South Carolina.
• No patient registry. The Department of Health (formerly DHEC, now DPH) does not maintain a Julian’s Law patient list. There is no count of how many patients have ever invoked the law’s protections. Compare: Florida’s Office of Medical Marijuana Use publishes a registered-patient figure of approximately 900,000; Alabama’s AMCC has a defined patient population; even narrowly drawn programs maintain official patient counts.
• No state-issued ID card. A qualifying patient cannot present a card to a traffic-stop officer to head off a charging decision. The defense is asserted, if at all, in court.
• No anti-discrimination protections. Julian’s Law does not protect a qualifying patient from termination by a private employer, denial of housing by a landlord, denial of child custody, or any of the collateral civil consequences that operational programs typically address.
• No federal preemption shield. Cannabis remains a federally controlled substance regardless of state authorization; for federal employees, federal contractors, military personnel, and federally regulated transportation workers, the federal regime preempts whatever Julian’s Law might offer at the state level. See federal installations.
• No reciprocity. Julian’s Law does not authorize possession by anyone authorized in another state’s medical program, and South Carolina does not honor any out-of-state medical card.

The 0.9% THC Ceiling and the Hemp Substitution

The 2014 statute specified a maximum 0.9% THC concentration — a level chosen at the time to permit higher-THC therapeutic CBD formulations than ordinary CBD products contained, while remaining well below the psychoactive thresholds associated with adult-use cannabis. Four years later, the federal 2018 Farm Bill legalized "hemp" defined as cannabis with delta-9 THC ≤0.3% on a dry-weight basis, and South Carolina’s 2019 Hemp Farming Act amendments aligned state law to that threshold. See Hemp Farming Act.

The practical effect: most CBD products now sold in South Carolina retail (smoke shops, vape stores, gas stations, pharmacies) are hemp-derived (THC ≤0.3%, often near 0%) and do not require Julian’s Law authorization. For ordinary high-CBD therapy — the original problem the Raines family was trying to solve in 2013–2014 — the federal hemp framework has overtaken the state CBD-only carve-out. Julian’s Law remains the only South Carolina authorization for cannabis-derived (rather than hemp-derived) products with measurable THC between 0.3% and 0.9%, but this is a narrow band rarely reached by commercial CBD formulations.

Epidiolex and the FDA Pharmacy Pathway

The June 2018 FDA approval of Epidiolex — a purified cannabidiol oral solution — for Lennox-Gastaut Syndrome and Dravet Syndrome (later expanded to tuberous sclerosis complex) created an entirely separate access pathway. Epidiolex is a federally approved pharmaceutical, dispensed through ordinary South Carolina pharmacy channels, prescribed by a neurologist, and covered by most insurance plans. For the two principal qualifying conditions Julian’s Law was originally written for, Epidiolex has become the operational standard of care — and it does not require the Julian’s Law authorization at all, because the FDA-approved product was rescheduled to allow ordinary medical use.

Some severe-epilepsy patients still benefit from non-Epidiolex CBD formulations — broader-spectrum oils with multiple cannabinoids in addition to CBD. For those families, Julian’s Law’s out-of-state-clinical-trial authorization remains relevant, though the supply chain is constrained and most product practically reaches qualifying patients only through clinical-trial enrollment at an approved teaching hospital (e.g., MUSC in Charleston).

The "Approved Teaching Hospital" Bottleneck

Section 44-53-1820 conditions the affirmative defense on a recommendation from "a physician licensed under Chapter 47 of Title 40 who treats patients with such conditions and who is authorized to recommend the use of cannabidiol (CBD) by an approved hospital that operates a clinical research program for cannabidiol." In practice, a qualifying patient must establish a physician relationship at a small number of South Carolina academic medical centers willing to maintain such a program — principally the Medical University of South Carolina (MUSC) in Charleston and selected Prisma Health and ECU/USC-affiliated facilities. The administrative burden of maintaining a "clinical research program for cannabidiol" has limited the number of facilities operating such a program; the result is that geographic access to the affirmative defense is concentrated and uneven. Charleston tertiary-care context.

What Julian’s Law Does Not Cover

Julian’s Law authorizes possession only by qualifying severe-epilepsy patients of a narrowly specified product. It does not authorize:

• Possession by patients with PTSD, cancer, multiple sclerosis, Crohn’s disease, ulcerative colitis, sickle-cell anemia, ALS, autism, glaucoma, or any condition outside the severe-epilepsy framework. These are the conditions covered by the proposed Compassionate Care Act (S.53), which has been stalled since 2014. See what S.53 would do.
• Possession of smokable flower, raw plant material, edibles, tinctures (above 0.9% THC), vape concentrates, transdermal patches, or any product form other than the specified low-THC, high-CBD oil.
• Cultivation by a qualifying patient. Personal cultivation remains a felony under § 44-53-370(b)(2) regardless of Julian’s Law eligibility.
• Possession by a caregiver who is not the patient, except as the statute’s narrow language permits.

S.53 Conforming Amendments

S.53 (2025–26), if enacted, would amend §§ 44-53-1810, 1820, and 1830 to make conforming changes — preserving the Julian’s Law carve-out as a separate statutory pathway alongside the new comprehensive medical-cannabis program. The two regimes would coexist: Julian’s Law as the narrow severe-epilepsy authorization, the Compassionate Care Act as the broader 12-condition program with pharmacist dispensing and DPH oversight. Until and unless S.53 passes, however, Julian’s Law remains the only South Carolina authorization for cannabis-derived (rather than hemp-derived) products with measurable THC. See Compassionate Care Act.

Practical Implications for South Carolina Patients

• For Lennox-Gastaut and Dravet patients: Epidiolex via standard pharmacy channels is the operational standard of care. Julian’s Law authorizes broader-spectrum CBD oils sourced out-of-state for patients whose physicians recommend non-Epidiolex formulations through an approved teaching hospital’s clinical research program.
• For other severe-epilepsy patients: the "any other severe form of epilepsy that is not adequately treated by traditional medical therapies" catchall provides coverage on paper, but the narrow product specifications (15%+ CBD, ≤0.9% THC) and the approved-teaching-hospital bottleneck constrain availability.
• For non-epilepsy patients: Julian’s Law provides no authorization at all. Only the proposed Compassionate Care Act would extend coverage to PTSD, cancer, MS, ALS, and the other conditions in the S.53 list.
• For federal-installation employees and military personnel: even with Julian’s Law authorization, federal-employee drug-testing rules apply. THC is detectable in standard panels regardless of whether the source product is authorized under SC state law. See workplace no protections.
• For arrest and prosecution exposure: a qualifying patient stopped with a Julian’s Law-compliant product is still subject to arrest, booking, product seizure, § 56-1-286 collateral driver’s license suspension on conviction, and the affirmative-defense burden at trial.

Until comprehensive medical cannabis is enacted, Julian’s Law’s symbolic and structural role — as the only cannabis-derived authorization on the books since 2014 — is far larger than its operational role.